Given the known etiology of LAM, and the use of the sirolimus MTOR inhibitor in the treatment of LAM, ability of MTOR inhibitors to reverse the LAM was expected and also in line with the functional analysis results from the previous section. This evidence concerns the gene MTOR and lymphangioleiomyomatosis.